Clinical trials: BRCA2 Gene Mutation
brca1 Mutation Carrier, brca2 Mutation Carrier
Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib before prophylactic oophorectomy may be an effective way to prevent the development of…
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
- Trial name
- NCT00084370
- Testing
- celecoxib, oophorectomy
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in…
- Trial name
- NCT02985658
- Testing
- Veliparib, Cisplatin, Vinorelbine
- Where
- United States
- Sponsor
- University of Washington
brca1 Mutation Carrier, brca2 Mutation Carrier
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenopausal women.
- Conditions
- brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
- Trial name
- NCT01097278
- Testing
- cholecalciferol
- Where
- 360 sites in United States
- Volunteers
- 208 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Evaluating the Effects of Genetic Testing on Patients' Stress Levels
This prospective Medical College of Wisconsin Cancer Center study will evaluate stress levels in breast cancer patients undergoing genetic testing.
- Trial name
- NCT02783664
- Testing
- Questionnaires to Evaluate Anxiety Related to Genetic Testing
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Medical College of Wisconsin
Prostate Cancer
Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)
PROREPAIR is a prospective multicenter observational cohort study of unselected patients with metastatic Castration Resistant Prostate Cancer (mCRPC) with unknown germline mutational status at study entry and who are candidates…
- Trial name
- NCT03075735
- Volunteers
- 408 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Breast Cancer, Surgery--Complications
Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy
Nipple-sparing mastectomy (NSM) with immediate reconstruction is one of the standard of care surgical treatments of breast cancer (BC) and is used for risk reduction in patients with a high risk for BC.
- Conditions
- Breast Cancer, Surgery--Complications, Genetic Predisposition to Disease, Surgery
- Trial name
- RNSM (NCT04151368)
- Testing
- Robotic Nipple-Sparing Mastectomy (RNSM)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Ovarian Cancer, Fallopian Tube Cancer
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate the safety of different doses and dosing regimens of oral rucaparib administered daily to patients with solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
- Trial name
- NCT01482715
- Testing
- Rucaparib
- Where
- 16 sites in United States, Canada and 3 more
- Volunteers
- 136 people
- Sponsor
- pharmaand GmbH
Breast Cancer, BRCA1 Mutation
Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing
Study Purpose: A multicenter prospective study to evaluate the outcome of second breast cancer surveillance with abbreviated breast MR (AB-MR) or ultrasound (US) in addition to annual mammography in women with BRCA1/2 mutation…
- Conditions
- Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Recurrent Breast Cancer
- Trial name
- NCT03475979
- Where
- South Korea
- Volunteers
- 1,564 people
- Sponsor
- Seoul National University Hospital
Advanced Solid Tumor
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated…
- Trial name
- NCT04890613
- Testing
- CX-5461
- Where
- 8 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Senhwa Biosciences, Inc.
Breast Cancer
National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations
The purpose of the study is to determine whether MR of the breast is a better screening tool than mammography combined with ultrasound of the breast in women with BRCA1 or BRCA2 gene mutations.
- Trial name
- MR BRCA (NCT00413491)
- Testing
- MR mammography, MR
- Where
- 4 sites in Denmark
- Volunteers
- 300 people
- Sponsor
- Danish Breast Cancer Cooperative Group
Ovarian, Breast
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
- Conditions
- Ovarian, Breast, Prostate, Pancreatic
- Trial name
- NCT01078662
- Testing
- olaparib
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 298 people
- Sponsor
- AstraZeneca
Pancreatic Neoplasms, Peutz-Jegher's Syndrome
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years.
- Conditions
- Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation
- Trial name
- NCT02309632
- Testing
- Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
- Where
- United States
- Sponsor
- University of Arkansas
TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation
Chemo-free BRCA-targeted Neoadjuvant Strategy
This is a multicenter randomized phase ll clinical trial to evaluate the pathological complete response (pCR) in the tumour burden (primary and lymph nodes) with olaparib alone or in the olaparib and durvalumab arm in TNBC…
- Conditions
- TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- NCT05209529
- Testing
- olaparib, Durvalumab
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)
This is a prospective registry trial to determine the outcomes of single port robot-assisted nipple sparing mastectomy (SPrNSM) utilitzing the SP da Vinci surgical system.
- Conditions
- Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- SPrNSM (NCT04866992)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
BRCA1 Gene Mutation, BRCA2 Gene Mutation
The Link Between BRCA Mutation and Endothelial Function
This study evaluates the effect of BRCA1\&2 mutations on cardiovascular diseases by to comparing the endothelial function of male BRCA mutation carriers with that of age matched non-BRCA mutation carriers.
- Trial name
- NCT02474264
- Testing
- Endothelial function assessment, Cardiovascular biomarkers, Endothelial cells
- Where
- Israel
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center
Nipple-sparing Mastectomy, Prophylactic Mastectomy
Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy
Nipple-sparing mastectomy (NSM) is indicated for breast cancer requiring total mastectomy and without nipple involvement by cancer.
- Conditions
- Nipple-sparing Mastectomy, Prophylactic Mastectomy, Breast Cancer, BRCA1 Mutation
- Trial name
- NCT05448963
- Testing
- da Vinci SPⓇ Single-port System
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Chang Gung Memorial Hospital
Epithelial Ovarian Cancer, Chinese
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients is little known.
- Conditions
- Epithelial Ovarian Cancer, Chinese, Homologous Recombination Deficiency, BRCA1 Mutation
- Trial name
- NCT04651920
- Testing
- Evaluation of homologous recombination deficiency score
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Lei Li
Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Trial design: Phase II, prospective, multi-center, randomized, open label, parallel group study in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutation, with 2:1…
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- ELEMENT (NCT06201234)
- Testing
- Olaparib + Elacestrant, Olaparib
- Where
- 36 sites in Germany
- Volunteers
- 176 people
- Sponsor
- GBG Forschungs GmbH
BRCA1 Mutation, BRCA2 Mutation
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Ovarian cancer is the most fatal gynecologic cancer; in the US alone an estimated 22,000 women will be diagnosed in 2019, with over 13,000 dying of the disease.
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT04598321
- Testing
- Talazoparib Oral Capsule
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brown University